Oncobiologics Revenue

Biotechnology Research • Cranbury, New Jersey, United States • 11-20 Employees

Oncobiologics revenue & valuation

Annual revenue	$1,283,325
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$4,200,000
Total funding	No funding

Key Contact at Oncobiologics

Charlie Mataya

Director, Financial Reporting

Company overview

Headquarters	7 Clarke Drive, Cranbury, New Jersey 08512, US
Website	oncobiologics.com
NAICS	541714
Keywords	Biosimilars, Oncology, Immunology, Monoclonal Antibodies
Founded	2011
Employees	11-20

Oncobiologics Email Formats

Oncobiologics uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.

Format	Example	Percentage
{first name}.{last name}@company.com	john.doe@company.com	42.1%
{first name}@company.com	john@company.com	25.3%
{first name initial}{last name}@company.com	{first name initial}doe@company.com	14.8%
{first name}{last name}@company.com	johndoe@company.com	10.2%
{last name}@company.com	doe@company.com	7.6%

About Oncobiologics

OVERVIEW Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company. We have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our BioSymphony™ Platform. Oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mAb biosimilars and was designed to provide significant pricing flexibility. PIPELINE Oncobiologics is currently developing a portfolio of eight commercially attractive mAb biosimilars. The company’s most advanced assets, ONS-3010 (a biosimilar of Humira®) and ONS-1045 (a biosimilar of Avastin®) have both successfully completed Phase I trials. We have initiated Phase 3 preparatory activities for ONS-3010 and ONS-1045.` STRATEGY Oncobiologics utilizes its BioSymphony Platform to develop, manufacture and commercialize technically challenging, cost-effective biosimilars on an accelerated timeline and to offer contract development and manufacturing services to development stage biologics companies.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Entry

C-Suite

Director

Employees by Department

Oncobiologics has 6 employees across 5 departments.

Departments

Number of employees

Funding Data

Oncobiologics has never raised funding before.

Frequently asked questions

Oncobiologics is located in Cranbury, New Jersey, US.

Oncobiologics generates an estimated annual revenue of $1,283,325. This revenue figure reflects the company's market position and business performance in its industry.

Oncobiologics has an estimated valuation of $4,200,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Oncobiologics was founded in 2011, making it 15 years old. The company has established itself as a significant player in its industry over this time.

Oncobiologics has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Oncobiologics

Charlie Mataya

Director, Financial Reporting

4.8

40,000 users